Skip to content

Multicenter clinical trial of targeting brain network hubs with neuromodulation in drug-resistant epilepsy.

Multicenter clinical trial of targeting brain network hubs with neuromodulation in drug-resistant epilepsy.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098092
Enrollment
Unknown
Registered
2025-03-03
Start date
2025-03-03
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

Intervention group:After the patient has a habitual seizure, the characteristic signal is automatically recognized, and all electrode contacts in the target area (calculated for each patient) are elec

Sponsors

The Second Affiliated Hospital of the Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for drug-refractory epilepsy; 2. Aged between 12-65 years old, male or female; 3. Have undergone preoperative evaluation of the multidisciplinary system, and SEEG monitoring will be carried out according to the needs of diagnosis and treatment; 4. Frequency of seizures in the past 3 months>=1 time/week, with/without secondary seizures; 5. After being informed of the current treatment options and potential risks, the patient agrees to participate in this study and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with secondary epilepsy caused by cerebrovascular diseases, tumors, infections, or autoimmune diseases. 2.Serious heart, liver, kidney physical diseases or severe or progressive neurological and psychiatric diseases with severe arrhythmia, QTc>450ms; transaminase exceeding the upper limit of normal values (0-40U/L) by three times, total bilirubin (3.4-17.1 µ mol/L), creatinine (44-133umol/L) exceeding the upper limit of normal values by 1.5 times, or creatinine clearance rate<45ml/min.

Design outcomes

Primary

MeasureTime frame
Seizure rate;

Secondary

MeasureTime frame
Stereoelectroencephalographic changes;

Countries

China

Contacts

Public ContactZhang Chunqing

The Second Affiliated Hospital of the Army Medical University

cqzhang@tmmu.edu.cn+86 189 8320 4130

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026